Lisanti Capital Growth LLC Sells 62,545 Shares of Vericel Co. (NASDAQ:VCEL)

Lisanti Capital Growth LLC lessened its stake in shares of Vericel Co. (NASDAQ:VCEL - Free Report) by 54.4% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 52,445 shares of the biotechnology company's stock after selling 62,545 shares during the period. Lisanti Capital Growth LLC owned approximately 0.11% of Vericel worth $2,216,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. International Assets Investment Management LLC lifted its stake in shares of Vericel by 4,126.7% in the 3rd quarter. International Assets Investment Management LLC now owns 634 shares of the biotechnology company's stock valued at $27,000 after purchasing an additional 619 shares during the period. CWM LLC increased its holdings in shares of Vericel by 319.0% in the second quarter. CWM LLC now owns 662 shares of the biotechnology company's stock worth $30,000 after purchasing an additional 504 shares during the last quarter. Farther Finance Advisors LLC increased its holdings in shares of Vericel by 48.1% during the third quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company's stock valued at $53,000 after acquiring an additional 405 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Vericel by 22.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,773 shares of the biotechnology company's stock worth $77,000 after purchasing an additional 322 shares during the last quarter. Finally, Nisa Investment Advisors LLC boosted its holdings in Vericel by 9.7% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,484 shares of the biotechnology company's stock valued at $114,000 after purchasing an additional 220 shares in the last quarter.

Insiders Place Their Bets

In other news, Director Steven C. Gilman sold 5,833 shares of the company's stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $40.35, for a total value of $235,361.55. Following the sale, the director now directly owns 11,000 shares of the company's stock, valued at approximately $443,850. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, Director Steven C. Gilman sold 5,833 shares of the stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $40.35, for a total value of $235,361.55. Following the transaction, the director now directly owns 11,000 shares of the company's stock, valued at approximately $443,850. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Dominick Colangelo sold 17,500 shares of the business's stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $41.38, for a total value of $724,150.00. Following the completion of the sale, the chief executive officer now owns 220,937 shares in the company, valued at $9,142,373.06. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 29,166 shares of company stock valued at $1,200,764 in the last three months. Insiders own 5.20% of the company's stock.

Vericel Trading Up 5.1 %

Shares of Vericel stock traded up $2.78 during trading on Monday, hitting $56.78. 577,259 shares of the stock were exchanged, compared to its average volume of 430,511. The stock has a market capitalization of $2.78 billion, a price-to-earnings ratio of -5,707,000.00 and a beta of 1.66. Vericel Co. has a 1-year low of $32.31 and a 1-year high of $57.35. The company has a fifty day moving average price of $44.27 and a 200-day moving average price of $46.41.

Vericel (NASDAQ:VCEL - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.03. Vericel had a return on equity of 0.35% and a net margin of 0.37%. The business had revenue of $57.91 million during the quarter, compared to analyst estimates of $55.32 million. Equities research analysts forecast that Vericel Co. will post 0.12 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

VCEL has been the subject of several recent research reports. BTIG Research cut their price target on Vericel from $56.00 to $55.00 and set a "buy" rating for the company in a report on Monday, July 15th. Truist Financial lifted their price target on Vericel from $56.00 to $57.00 and gave the company a "buy" rating in a research report on Tuesday, July 16th. Canaccord Genuity Group began coverage on Vericel in a report on Friday, August 9th. They set a "buy" rating and a $57.00 target price on the stock. Stephens lifted their target price on shares of Vericel from $56.00 to $58.00 and gave the stock an "overweight" rating in a report on Friday, August 2nd. Finally, HC Wainwright restated a "buy" rating and set a $60.00 price objective on shares of Vericel in a research report on Friday. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, Vericel has an average rating of "Moderate Buy" and an average target price of $57.71.

Vericel Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.